All the news Showing 10 of 156 articles from: United StatesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Harm reduction interventions and policy Bacterial infection of the heart on the rise among people with hepatitis C in United States Keith Alcorn / 23 June 2020 Diagnoses of infective endocarditis, a life-threatening bacterial infection of the heart valves, have become more common over the past ten years among people with hepatitis C and people with opioid use disorder ... Liver transplants NASH is fastest-growing reason for a liver transplant in United States Keith Alcorn / 22 June 2020 Non-alcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD), is now the most common reason for a liver transplant in women, older patients and people receiving Medicare insurance in the ... Liver transplants Liver transplants and COVID-19 Keith Alcorn / 28 April 2020 Liver specialists in New York report a high frequency of severe COVID-19 cases in organ transplant recipients who became infected with SARS-CoV-2, while Italian specialists report that 15 of 17 patients who underwent ... NAFLD HIV-positive people with fatty liver disease are at high risk for fibrosis Liz Highleyman / 23 March 2020 People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ... Screening and testing policy 90% of people who inject drugs in United States missed opportunities for HIV or hepatitis C tests Keith Alcorn / 27 February 2020 Around 90% of people who inject drugs in the United States missed opportunities for HIV or hepatitis C virus testing between 2010 and 2017, a review of more than 840,000 healthcare visits shows. ... Treatment guidelines New US guidelines recommend screening of all adults for hepatitis C Keith Alcorn / 12 December 2019 All adults in the United States should be screened for hepatitis C by healthcare providers as part of routine medical care, updated guidelines from the American Association for the Study of Liver ... Experimental treatments for NASH/NAFLD New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... Hepatocellular carcinoma (HCC) When is the right time to treat hepatitis C in people with liver cancer? Keith Alcorn / 27 October 2019 Direct-acting antiviral treatment for hepatitis C need not be delayed until the completion of treatment for hepatocellular carcinoma (HCC; liver cancer), but people with hepatitis C need to be warned of a ... NAFLD Non-alcoholic fatty liver disease raises the risk of cancer in overweight people Keith Alcorn / 24 September 2019 Obesity without non-alcoholic fatty liver disease (NAFLD) does not raise the risk of cancer, but people with NAFLD who are also obese are almost twice as likely to be diagnosed with cancer ... Side effects FDA warns of rare cases of serious liver injury with newer hepatitis C drugs Keith Alcorn / 29 August 2019 The US Food and Drug Administration (FDA) has issued a warning about the risk of serious liver injury in people with hepatitis C after starting recently approved direct-acting antiviral regimens that contain ... ← Prev1...23456...16Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive